[BLCO] Bausch + Lomb Thesis 2026: Contact Lenses, Miebo and Xiidra Anchor an Eye-Health Pure-Play Awaiting Independence

Key Takeaways

• Bausch + Lomb Corporation (NYSE/TSX: BLCO) is expected to close FY2025 with selected various aggregate revenue of roughly $4.9-5.3B (mid-single-to-high-single-digit % growth) and aggregate adjusted EPS in the area of $0.30-1.10 (GAAP loss likely on heavy acquired-intangible amortization), with adjusted EBITDA around ~$850M-1.05B (~17-20% margin), under Chairman & CEO Brent Saunders (~2-3 year tenure since 2023, the former Allergan CEO and well-known pharma-industry deal-maker).
• The first deep-dive — Vision Care plus Pharmaceuticals (the consumer-eye-care and Rx franchise) — covers the contact-lens franchise (Biotrue, PureVision, INFUSE, Bausch + Lomb Ultra and the silicone-hydrogel daily portfolio plus contact-lens-care solutions) plus consumer-eye-care brands (Lumify, PreserVision) and the prescription eye-drug portfolio anchored by Miebo (perfluorohexyloctane for dry eye, US first-in-class, launched late 2023) and Xiidra (lifitegrast, acquired from Novartis in 2023 for ~$1.75B); FY2026 catalyst is Miebo/Xiidra commercial ramp, contact-lens daily/silicone-hydrogel growth, and Lumify line extensions.
• The second deep-dive — the Surgical franchise plus the Bausch Health (BHC) parent overhang and the separation question — covers intraocular lenses (IOLs — including the enVista monofocal/toric portfolio and newer multifocal entries), surgical equipment (Stellaris vitreoretinal and phacoemulsification platforms), and instruments/consumables, plus the ongoing question of when (or whether) Bausch Health spins off its remaining ~88% stake to fully separate the eye-health business; FY2026 catalyst is the enVista launch progression, surgical-equipment market share, and any movement on the full separation / strategic alternatives review.
• Capital position is leveraged with no shareholder return: no dividend, no buybacks (cash directed to debt service and growth investment), selected various aggregate net debt in the area of $4.0-4.6B (term loans and senior notes — Xiidra-acquisition-elevated), roughly ~5-7x net debt/EBITDA (high — a function of the slim margin and the Xiidra debt), sub-investment-grade credit profile (B+/B1-area), and ~355-365M shares outstanding.
• FY2026 catalysts: Miebo (perfluorohexyloctane) prescription ramp and reimbursement, Xiidra share dynamics, the silicone-hydrogel daily contact-lens portfolio (INFUSE, the SiHy daily), enVista IOL family launch (monofocal/toric/multifocal), surgical-equipment placements, free-cash-flow inflection, deleveraging progress, and the Bausch Health (BHC) separation outcome — the binary that could remove a structural overhang and re-rate the stock.

Company Background

Bausch + Lomb Corporation, headquartered in Vaughan, Ontario, Canada (with operational headquarters in Bridgewater, New Jersey), is one of the world's longest-running and largest pure-play eye-health companies — founded in 1853 in Rochester, New York by John Jacob Bausch and Henry Lomb as an optical-goods shop, with a multi-century history of pioneering vision products (Ray-Ban sunglasses — divested in 1999, the soft contact lens, Vaseline, ReNu lens-care solutions). The modern company is the eye-health business of the former Valeant Pharmaceuticals — Valeant acquired Bausch + Lomb in 2013, was rebranded as Bausch Health Companies (NYSE: BHC) in 2018, and spun off Bausch + Lomb as a separately-listed entity in May 2022 (NYSE and TSX), in what was intended to be the first step toward a full separation (BHC retaining a majority stake initially, with the plan to distribute the remaining BLCO shares to BHC shareholders contingent on BHC's debt-leverage conditions being met). As of FY2025 Bausch Health still owns roughly ~88% of BLCO common stock — the full separation has been delayed due to BHC's heavy debt load, the Xifaxan patent-cliff uncertainty, and capital-structure dynamics — leaving BLCO as a publicly-listed but parent-controlled company, with the separation question a persistent equity-story overhang. The business runs three reporting segments: Vision Care (~half-ish of revenue — contact lenses including the Biotrue, PureVision, INFUSE, Bausch + Lomb Ultra and SiHy daily families plus contact-lens-care solutions like Biotrue and ReNu, plus consumer/OTC eye care like Lumify decongestant drops and PreserVision AREDS vitamins for macular degeneration); Pharmaceuticals (~roughly a third — prescription eye drugs and OTC, with Miebo (perfluorohexyloctane, the first-and-only-of-its-kind US-approved dry-eye drug — launched late 2023) and Xiidra (lifitegrast, acquired from Novartis in 2023 for ~$1.75B in cash) the headline growth drivers, plus legacy Rx eye drops); and Surgical (~the remaining portion — intraocular lenses (IOLs) including the enVista family, phacoemulsification and vitreoretinal surgical equipment, instruments and consumables). Geography is global with a US lead. The capital structure carries acquisition-driven leverage. Risks: the parent BHC overhang (timing and form of any full separation, governance dynamics), Miebo/Xiidra commercial execution against an evolving dry-eye competitive set, contact-lens share dynamics (especially in the booming daily silicone-hydrogel category), the IOL competitive set, leverage and rate sensitivity, and the long tail of consumer/Rx product cycles.

Vision Care Plus Pharmaceuticals: Contact Lenses, Lumify, Miebo, and Xiidra

The first deep-dive bundles the two largest segments — Vision Care plus Pharmaceuticals — which together produce most of revenue and most of the growth. Vision Care is the consumer franchise built on contact lenses and lens care plus consumer-OTC eye care. Contact lenses are the core: a comprehensive portfolio of soft lenses across the modality spectrum — monthly silicone-hydrogel lenses (Bausch + Lomb Ultra, PureVision), two-week lenses, silicone-hydrogel daily disposables (the INFUSE and Bausch + Lomb INFUSE One Day family — the high-growth daily SiHy category, plus toric and multifocal versions), and lens-care solutions (Biotrue multipurpose, ReNu) — sold through eye-care professionals and increasingly online. The SiHy daily segment is the fastest-growing contact-lens category and the most contested (Alcon's Total1, J&J's Acuvue Oasys 1-Day with HydraLuxe, CooperVision's MyDay, plus BLCO's INFUSE One Day) — share gains here are the headline Vision Care KPI. Consumer eye care / OTC: Lumify (a brimonidine eye drop for red-eye relief — a category-defining brand with strong margins and growing distribution), PreserVision (AREDS/AREDS2 vitamin formulations for age-related macular degeneration — well-established, prescribed-by-eye-doctors brand), plus various OTC drops/balms. Pharmaceuticals (the Rx and OTC drug franchise) is anchored by Miebo (perfluorohexyloctane ophthalmic solution — the first-and-only US-approved water-free dry-eye drug, designed to address tear-film evaporation rather than just inflammation — launched late 2023, ramping into a large dry-eye disease (DED) market) and Xiidra (lifitegrast 5% ophthalmic solution — an LFA-1 antagonist for inflammatory dry eye, acquired from Novartis in 2023 for ~$1.75B in cash) — giving BLCO a two-drug dry-eye franchise competing against Restasis (cyclosporine, generic now), Cequa (cyclosporine, Sun Pharma), Tyrvaya (Oyster Point — Viatris), Vevye (Harrow), and various OTC options; plus legacy Rx eye drops (Lotemax, glaucoma, etc.). FY2025 dynamics: contact-lens revenue growing mid-single-digit (daily SiHy uptake), Lumify outperforming, Miebo ramping faster than initial expectations, Xiidra growth post-acquisition, pricing/mix favorable, segment margin steady. FY2026 catalyst: Miebo prescription growth and reimbursement, Xiidra hold-or-gain, INFUSE daily SiHy growth and toric/multifocal extensions, Lumify line extensions, contact-lens-care steady, and any new Rx launches. Risks/competitors: contact-lens share losses to Alcon (ALC), Johnson & Johnson Vision (JNJ), and CooperVision (COO); dry-eye competition (the Sun Pharma Cequa, Viatris/Oyster Point Tyrvaya, Harrow Vevye); generic erosion of legacy Rx drugs; pricing pressure from payers; OTC competition for Lumify; and US tariff/trade dynamics on imported contact lenses.

Surgical Plus the BHC Parent Overhang and the Separation Question

The second deep-dive is the Surgical franchise plus the unresolved Bausch Health (BHC) parent question. Surgical is the smaller, more cyclical segment — selected various aggregate roughly ~15-20% of revenue — and it consists of intraocular lenses (IOLs), surgical equipment, and instruments/consumables used in cataract, vitreoretinal and refractive eye surgery. IOLs: BLCO's IOL portfolio is anchored by the enVista family — a premium hydrophobic-acrylic IOL platform with monofocal, toric (for astigmatism correction) and newer enVista multifocal/EDOF (extended-depth-of-focus) options — competing against Alcon's market-leading AcrySof family (including Vivity EDOF and PanOptix trifocal), J&J Vision's Tecnis (including Symfony EDOF and Synergy multifocal), and other regional players (Carl Zeiss Meditec, HOYA, Rayner); the multifocal/EDOF segment is the fastest-growing IOL category (premium cataract surgery), and BLCO's enVista multifocal entry is meant to gain share. Surgical equipment: the Stellaris vitreoretinal and Stellaris Elite phacoemulsification platforms, plus visualization (Synergetics, ARVO microscopes), instruments and consumables — equipment placements drive a long tail of consumable pull-through. FY2025 dynamics: cataract-volume growth, Surgical revenue mixed (IOL share dynamics versus Alcon and J&J, equipment placements steady), the enVista launch progress in the multifocal/EDOF space. FY2026 catalyst: the enVista IOL family launch (especially multifocal/EDOF — share-gain potential), surgical-equipment placements, the cataract-volume backdrop, and pricing/mix. Risks/competitors: Alcon (ALC, the dominant IOL leader), J&J Vision (JNJ), Carl Zeiss Meditec (CZMWY), HOYA, plus regional/Chinese players. The BHC parent overhang: Bausch Health (NYSE: BHC) still owns selected various aggregate 88% of BLCO common stock; the originally-planned full separation (a distribution of BHC's remaining BLCO stake to BHC shareholders) has been repeatedly delayed as Bausch Health has wrestled with its substantial debt load ($20B+) and the Xifaxan patent-cliff uncertainty (Xifaxan, BHC's largest drug, has faced generic challenges that have been litigated extensively). The separation outcome is a structural BLCO equity overhang and an upside lever: a full BHC spin-off would remove the parent-control overhang and unlock institutional ownership (some funds avoid parent-controlled companies); alternatively, a sale of BLCO (a strategic alternatives process has been speculated) could realize value at a premium. FY2026 catalyst: any movement on the full separation (BHC's debt situation, Xifaxan resolution, a distribution decision) — a significant binary. Risks: continued delay (the overhang persists), or an unfavorable separation structure that ties BLCO to BHC liabilities. Comp set: Alcon (ALC) is the closest pure-play eye-health comp; J&J Vision (within JNJ), Cooper (COO, contact lenses + women's health), Carl Zeiss Meditec (CZMWY), HOYA on IOLs/equipment; on dry eye, Viatris (VTRS), Harrow (HROW), Sun Pharma (SUNPHARMA.NS); on consumer eye drops, the OTC majors.

Capital Position + Balance Sheet

BLCO runs a leveraged, no-return capital structure. The company pays no dividend and conducts no share repurchases — cash is directed to debt service, R&D and commercial investment (especially Miebo + Xiidra build-out). Net debt is selected various aggregate roughly $4.0-4.6B (term loans and senior notes plus an ABL/revolver — the Xiidra acquisition in 2023 added ~$1.75B+ of debt and a meaningful payment to Novartis), keeping net debt to EBITDA at a high ~5-7x — well above peer norms and a clear concern for the equity story — with a sub-investment-grade credit profile (B+/B1-area at the major agencies). Free cash flow is modest given the rate cycle and the Xiidra-related working-capital build, inflecting positive as Miebo/Xiidra revenue scales and as interest expense ideally moderates with rate cuts; FCF priorities are debt service, debt paydown, and growth investment. The share count is selected various aggregate ~355-365M (with BHC owning ~88%). The BHC parent overhang is the dominant balance-sheet consideration — beyond BLCO's own leverage, the parent's debt distress shadows the equity. The principal balance-sheet considerations: the high leverage and the Xiidra debt service, the rate sensitivity of the term-loan portion, the BHC separation outcome, refinancing risk on upcoming maturities, and the question of when (and how) free cash flow inflects materially.

Key Core Metrics

• Revenue: selected various aggregate ~$4.9-5.3B FY2025 (~mid-single-to-high-single-digit % growth)
• Adjusted EBITDA: selected various aggregate ~$850M-1.05B FY2025 (~17-20% margin)
• Adjusted EPS: selected various aggregate ~$0.30-1.10 FY2025 (GAAP loss likely on amortization)
• Vision Care: ~half-ish of revenue; contact lenses (Biotrue, PureVision, INFUSE, Bausch + Lomb Ultra, SiHy daily incl. INFUSE One Day) + lens care (Biotrue, ReNu) + consumer/OTC eye care (Lumify, PreserVision)
• Pharmaceuticals: ~⅓ of revenue; Miebo (perfluorohexyloctane, dry eye, first-in-class, launched late 2023) + Xiidra (lifitegrast, acquired Novartis 2023 ~$1.75B) + Lotemax, glaucoma, legacy Rx
• Surgical: ~15-20% of revenue; enVista IOL family (monofocal/toric/multifocal/EDOF) + Stellaris vitreoretinal/phaco platforms + instruments/consumables
• Daily silicone-hydrogel contact lens: the fastest-growing contact-lens category; INFUSE One Day family the BLCO entry
• Dry-eye disease (DED): a large market BLCO addresses with Miebo + Xiidra (a unique two-drug DED franchise)
• Lumify: category-defining brimonidine red-eye drop; growing distribution + line extensions
• IOL: enVista family — entering multifocal/EDOF (the premium-cataract growth segment) — challenging Alcon (ALC) and J&J Vision
• Geography: global with US lead
• Bausch Health (BHC) parent: still owns ~88% of BLCO common stock; full separation delayed by BHC's ~$20B+ debt and Xifaxan patent-cliff uncertainty
• Separation question: a structural overhang and upside lever (full spin or sale would unlock value)
• CEO: Brent Saunders (Chairman & CEO, ~2-3 year tenure since 2023; ex-Allergan CEO, well-known pharma deal-maker)
• Net debt: selected various aggregate ~$4.0-4.6B FY2025 (Xiidra-acquisition-elevated)
• Net debt / EBITDA: selected various aggregate ~5-7x (high)
• Credit profile: sub-investment-grade (B+/B1-area)
• Dividend: none; Buybacks: none — cash to debt service + growth investment
• Shares outstanding: selected various aggregate ~355-365M (BHC owns ~88%)
• Capital allocation: debt service → growth investment (Miebo, Xiidra, enVista, INFUSE) → (eventually) deleveraging — no shareholder return near-term

Market Evaluation

At roughly ~$14-22 per share on ~355-365M shares, Bausch + Lomb carries an equity value of selected various aggregate ~$5-8B (and an enterprise value of selected various aggregate ~$9-12.5B including net debt), which on FY2025 cash flow is roughly ~10-15x EV/EBITDA and (because GAAP is loss-making) is best framed on EV/Sales (~1.7-2.5x) versus eye-health peers — a discount to the premium pure-play Alcon, reflecting BLCO's higher leverage, the BHC parent overhang, the lack of capital returns, and a less-than-best-in-class growth/margin profile. The comp set: Alcon (ALC) is the direct read-through (the larger pure-play eye-health leader at premium multiples); Cooper Companies (COO, CooperVision contact lenses + women's health); Carl Zeiss Meditec (CZMWY, surgical/diagnostic eye instruments); HOYA (Japanese eye/optics); Johnson & Johnson (JNJ, J&J Vision within Medtech); on the dry-eye Rx side, Viatris (VTRS, Tyrvaya), Harrow (HROW, Vevye), Sun Pharma (SUNPHARMA.NS, Cequa), with Roche/Genentech as a longer-term observer; on the consumer eye-care side, Procter & Gamble (PG) and other OTC players. FY2026 base case: selected various aggregate ~$5.2-5.6B revenue + ~$0.50-1.30 adj. EPS + ~$900M-1.1B adjusted EBITDA + Miebo + Xiidra ramping + INFUSE growth + enVista launching + leverage stable-to-down + BHC overhang unresolved — solid revenue growth, slow deleveraging. Bull case: selected various aggregate ~$5.5-6.0B+ revenue + ~$1.00-2.00+ adj. EPS on Miebo exceeding expectations, Xiidra outperforming, INFUSE One Day SiHy taking share, enVista multifocal/EDOF launching strongly in IOLs, margin expansion, FCF inflecting positive, a full BHC spin-off completed removing the overhang and re-rating the stock, deleveraging accelerating, and a re-rating toward ALC-style multiples. Bear case: selected various aggregate ~$4.7-5.1B revenue + ~$(0.30)-0.30 adj. EPS on Miebo/Xiidra disappointing (dry-eye competition, payer pushback), contact-lens share losses to Alcon/J&J/Cooper, enVista launch missing, surgical-equipment placement softness, leverage rising on weak FCF and rate pressure, BHC separation stalling indefinitely, and a de-rating. The thesis turns on the Vision Care + Pharmaceuticals pipeline (contact lenses + Lumify + Miebo + Xiidra + INFUSE daily SiHy + dry-eye franchise) plus the Surgical + BHC pipeline (enVista IOL + Stellaris equipment + the parent-separation outcome + leverage path) plus the dry-eye and silicone-hydrogel-daily growth backdrops plus deleveraging plus the binary BHC separation catalyst plus Brent Saunders's execution of the post-spin eye-health pure-play playbook.